SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
a row of red down arrows and green up arrows. hand choose arrow. the concept of inflation. the concept of taking profit or increasing income. different options. difference of direction icon, business, arrow, arrows, marketing, green, success, red, sign, graph, investment, chart, corporate, growth, financial, currency, market, profit, exchange, stock, economic, motion, forecast, cursor, inflation, recession, investor, pointer, download, trend, loss, vertical, progress, statistic, direction, symbol, crisis, down, downward, increase, lift, pointing, previous, raise, two, up, upward, upwards, vote
Adcomms
Otsuka, Lundbeck Fail To Sway Adcomm on Rexulti Combo for PTSD
Otsuka and Lundbeck’s data are insufficient to establish significant efficacy of Rexulti plus sertraline in PTSD, according to the FDA’s outside experts.
July 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Business despair concept as a stranded businessman lost at sea standing on an isolated rock as a corporate idea for financial crisis or being lost and needing career or financial help to escape in a 3D illustration style.
Duchenne muscular dystrophy
Sarepta Stands Ground Against HHS Request To Stop Elevidys Shipments
In light of recent patient deaths, the FDA has also revoked its platform designation for Sarepta’s AAVrh74 technology. The designation, granted last month, was the first of its kind to be announced publicly.
July 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review
Complete response letters
Lack of US Data Stymie Roche’s Earlier-Stage Lymphoma Push for Columvi
Roche and Genentech were unable to sufficiently demonstrate the benefit of using Columvi in an earlier treatment setting for DLBCL in a U.S. population, according to the FDA.
July 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Escape or finding a way or destiny or solving life problems psychologic concept with human silhouette walking through the dark tunnel to the light at the end of the tunnel. Vector eps 10 illustration
Drug Development
How Data Secrecy Is Stalling Progress in Cell and Gene Therapy
Amid a season of regulatory and scientific advances, experts reveal a culture of data hoarding among cell and gene therapy developers that is reinforcing fragmentation, stalling innovation and delaying access to treatments.
July 21, 2025
 · 
7 min read
 · 
Ana Mulero
Illustration of two syringes in a pop art style with pinks and blues
Vaccines
After Moderna Pulled Its Shot, Combination Flu/COVID Vaccines Hang in Limbo
Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based combination shot that targets both influenza and COVID-19. Now, the entire vaccine sector is sizing up a new regulatory world, companies’ next steps uncertain.
July 21, 2025
 · 
7 min read
 · 
Dan Samorodnitsky
A silhouetted roller coaster, taken on high speed black and white film for dramatic effect.
Duchenne muscular dystrophy
Sarepta Craters as FDA Considers Requesting Halt to Elevidys Shipments
The rollercoaster week for Sarepta Therapeutics continued, with shares of the embattled gene therapy-turned-siRNA biotech down 37% Friday afternoon as media outlets reported FDA plans to request a stop to all shipments of the Duchenne muscular dystrophy therapy Elevidys following a third patient death linked to the underlying platform.
July 18, 2025
 · 
2 min read
 · 
Heather McKenzie
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Clinical research
BMS’ Anemia Drug Reblozyl Flunks Phase III Myelofibrosis Trial
Despite the failure, BMS remains “encouraged” by Reblozyl’s clinical activity in myelofibrosis-associated anemia and will approach regulators to discuss potential submissions for this indication, for which few treatment options exist.
July 18, 2025
 · 
2 min read
 · 
Tristan Manalac
A person and a group of people are separated by a yellow line. Establishing contact. Distrust. Quarantine. Distance with strangers. Barrier to understanding, difficult integration. Rejection, refusal.
Cancer
GSK’s Blenrep Loses Adcomm Vote, Further Clouding Comeback Bid
The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug conjugate in multiple myeloma.
July 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Sarepta Therapeutics
Duchenne muscular dystrophy
Sarepta Reports a Third Gene-Therapy Related Patient Death
The patient, who was being treated with an investigational gene therapy for limb-girdle muscular dystrophy, died of acute liver failure, the same complication responsible for the deaths of two boys taking Sarepta’s Duchenne muscular dystrophy treatment Elevidys.
July 18, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS